Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 3/20 | 0.55 |
| ▸ | MMP3 | P08254 | 5/20 | 0.53 |
| ▸ | MMP12 | P39900 | 5/20 | 0.53 |
| ▸ | MMP7 | P09237 | 4/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.49 |
| ▸ | MMP10 | P09238 | 2/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6791062 | 0.86 | MMP7 (0.59) | ADAM17MMP3MMP12MMP7MMP2 | |
| SCHEMBL6790949 | 0.83 | MMP12 (0.69) | ADAM17MMP3MMP12MMP7HDAC6 | |
| SCHEMBL6789728 | 0.80 | MMP12 (0.67) | ADAM17MMP3MMP12MMP7HDAC6 | |
| SCHEMBL6790073 | 0.79 | ADAM17 (0.60) | ADAM17MMP3MMP12MMP7HDAC6 | |
| SCHEMBL6790813 | 0.79 | HDAC1 (0.66) | ADAM17MMP3MMP12MMP7MMP2 | |
| SCHEMBL6796748 | 0.79 | ADAM17 (0.57) | ADAM17MMP3MMP12MMP7HDAC6 | |
| SCHEMBL6264043 | 0.78 | MMP12 (0.69) | ADAM17MMP3MMP12MMP7HDAC6 | |
| SCHEMBL6790798 | 0.78 | MMP12 (0.62) | ADAM17MMP3MMP12MMP7MMP10 | |
| SCHEMBL6790313 | 0.78 | MMP12 (0.69) | ADAM17MMP3MMP12MMP7HDAC6 | |
| SCHEMBL6795725 | 0.78 | MMP12 (0.58) | ADAM17MMP3MMP12MMP7HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6740649-B2 | ANTIINFLAMMATORY AGENTS; OSTEOPOROSIS | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-25 | — | — | US | claimed |
| US-20030139388-A1 | Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2003-07-24 | — | — | US | claimed |
| US-6740649-B2 | ANTIINFLAMMATORY AGENTS; OSTEOPOROSIS | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-25 | — | — | US | disclosed |
| US-20030139388-A1 | Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139388-A1 | Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | ADAMTS1, MMP1, ADAM17 | ADAM17 3/4885MMP3 16/4885MMP12 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.